Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Agent for treating and/or preventing of neuropathic pain

A technology of therapeutic and preventive agents, applied in the field of calcitonin preparations, can solve the problems of time-consuming, insufficient effect, and no safe and quick-acting effective treatment methods, so as to reduce the burden and side effects and achieve high effects Effect

Inactive Publication Date: 2008-04-30
ASAHI KASEI PHARMA
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Although there are clinical reports that intermittent administration of calcitonin preparations is effective for various neuropathic pains, it takes time for the effect to appear, and the effect is substantially not sufficient at all (Non-Patent Document 9, Non-Patent Document 10)
[0009] As mentioned above, in the treatment of neuropathic pain, there is no established safe and fast-acting effective treatment method, and the development of new treatment options is desired

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for treating and/or preventing of neuropathic pain
  • Agent for treating and/or preventing of neuropathic pain
  • Agent for treating and/or preventing of neuropathic pain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0094] For neuropathic pain caused by peripheral nerve injury, in order to confirm the effect of continuous administration of ectonin (ECT), this model animal, Namiki et al. "(2000), the sciatic nerve entrapment model (CCI model) described on page 37 was modified and tested. 4-week-old SD (IGS) male rats were purchased, and pre-feeding, management-based acclimation, and acclimation to the mechanical paw withdrawal threshold measurement device were carried out for 5 days each, and then sciatic nerve compression surgery was performed at 7 weeks of age or Sham surgery for experimentation.

[0095] Under ether anesthesia, the rat was placed in a prone position, and the skin was incised along the right femur just above it. Peel off the biceps thigh at the center of the thigh to expose about 5mm without injuring the sciatic nerve. Using a 4-0 knife wire (ブレドドシルク), press gently on the central part of the thigh from the distal side 4 times. Thereafter, the fascia and skin are sutured...

Embodiment 2

[0103] The analgesic effect of elcatonin administered at doses of 750 μU / kg / week, 75 μU / kg / week, and 7.5 μU / kg / week was studied in the same manner as in Example 1 above.

[0104] The results are shown in Figure 3. The CCI model was observed to have a significant decrease in pain threshold compared with pre-operation (##: p<0.01). Significant analgesic effects were observed in the 750 μU / kg / week administration group from the second day after the start of administration, while the 75 μU / kg / week administration group was only observed on the third and fourth days after administration Significant effect (**: p<0.005). No significant effect was observed in the 7.5μU / kg / week administration group. Therefore, it is considered that the dose threshold of calcitonin exhibiting analgesic effect in rats with neuropathic pain is 75 μU / kg / week.

Embodiment 3

[0106] Using the same CCI model animals as in Example 1 above, the effect of continuous administration of elcalcitonin on hyperalgesia in CCI model animals was studied. The preparation of the CCI model, the administration method of elcalcitonin, and the start time of administration were the same as those in Example 1. The dose of calcitonin was 0.00075U / kg / week, 0.0075U / kg / week, 0.075U / kg / week, 7.5U / kg / week, 75U / kg / week, and the CCI control group was given excipients . The measurement was performed according to the manual of "BASILE Foot Measurement" (UGO BASILE: 7370). The device is used to measure the time from noxious thermal stimulation to the rat's hind limbs to the paw withdrawal (paw withdrawal latency) in a free state. The right hind limb is used as the measuring foot. Initially, rats were placed in an acrylic box on a glass plate and acclimated for about 5 minutes. Place the mobile I.R (infrared) generator (I.R. container) under the glass plate, and align the "sig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

To provide a pharmaceutical which has an action effective for the treatment of various neurogenic pains and shows a low toxicity. A therapeutic agent and / or prophylactic agent for a neurogenic pain comprising a calcitonin (particularly elcatonin) as an active ingredient, the calcitonin being administered continuously in such an amount that does not vary the serum calcium level; and use of a calcitonin (particularly elcatonin) for the preparation of a therapeutic agent and / or prophylactic agent for a neurogenic pain.

Description

technical field [0001] The present invention relates to calcitonin preparations with rapid analgesic effect on neuropathic pain. Background technique [0002] Neuropathic pain (also called neurogenic pain or neuropathic pain, but referred to as neuropathic pain in the specification of this application below) is intractable pain due to dysfunction of the peripheral or central nervous system. Neuropathic pain is caused by neurological disorders caused by metabolic disorders such as trauma, infection, cancer, anemia, and diabetes. Its pathogenesis is still unclear, but it is thought to be caused by abnormal continuous discharge of sensory nerves, etc. Typical symptoms of neuropathic pain include allodynia, hyperalgesia, or hyperesthesia. These symptoms manifest as pain characterized by "burning," "pins and needles," or "electric shock." It is known that analgesics which are generally effective for nociceptive pain, especially narcotic analgesics, etc., have little effect on ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/23A61P25/00A61P29/00
CPCA61K38/23A61P25/00A61P25/04A61P29/00
Inventor 伊藤彰敏武田实音子
Owner ASAHI KASEI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com